Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY trial of AMG 334 in episodic migraine after failure of 2-4 preventive therapies
NL-OMON50588Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing AMG 334 with Placebo (2 arms). Primary endpoint: Proportion of patients with at least 50% reduction from baseline in monthly migraine days. Started Apr 2017; status: active, not recruiting.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON50588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50588.